Get the Stockscreener App
3.82
2.69%
0.10
After Hours:
3.82
Aardvark Therapeutics Inc stock is traded at $3.82, with a volume of 87,230.
It is up +2.69% in the last 24 hours and down -16.41% over the past month.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
See More
Previous Close:
$3.72
Open:
$3.85
24h Volume:
87,230
Relative Volume:
0.45
Market Cap:
$83.34M
Revenue:
-
Net Income/Loss:
$-69.87M
P/E Ratio:
-1.1904
EPS:
-3.2089
Net Cash Flow:
$-61.75M
1W Performance:
+9.77%
1M Performance:
-16.41%
6M Performance:
-71.10%
1Y Performance:
-66.10%
1-Day Range:
$3.645
$3.95
1-Week Range:
$3.40
$4.10
52-Week Range:
$3.35
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Name
Aardvark Therapeutics Inc
Sector
Industry
Phone
(858) 225-7696
Address
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
3.82 | 83.77M | 0 | -69.87M | -61.75M | -3.2089 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-02-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-26 | Downgrade | Stifel | Buy → Hold |
| Jan-28-26 | Initiated | B. Riley Securities | Buy |
| Dec-23-25 | Initiated | Oppenheimer | Outperform |
| Dec-12-25 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Raymond James | Strong Buy |
| Nov-07-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Stifel | Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Initiated | BofA Securities | Buy |
| Mar-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-10-25 | Initiated | Morgan Stanley | Overweight |
| Mar-10-25 | Initiated | RBC Capital Mkts | Outperform |
View All
Aardvark Therapeutics Inc Stock (AARD) Latest News
Aardvark Therapeutics Inc. (AARD) Gains 7% as Stock Approaches Resistance LevelRisk Reward Setups - newsline.com
Aardvark Therapeutics Implements Executive Retention Bonus Agreements - TipRanks
Executive retention bonuses outlined at Aardvark Therapeutics (NASDAQ: AARD) - Stock Titan
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - PR Newswire
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc.AARD - FinancialContent
Aardvark Therapeutics Insiders Lose Out As Stock Sinks To US$3.59 - simplywall.st
AARD Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Risk Report - newsline.com
Aardvark Therapeutics (AARD) Slips 2.45% as Stock Tests Key Support at $3.41Elliott Wave Entry - newsline.com
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits
Aardvark Therapeutics (AARD) Declines Over 4% as Stock Tests Key Support LevelsVolatility Skew - newsline.com
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid - GlobeNewswire
AARD Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue StageGAAP Earnings Report - The Legal Advocate
AARD Q1 2026 Earnings: EPS Misses Estimates but Stock Rises on Pipeline ProgressEPS Revision Trend - The Legal Advocate
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS - Moomoo
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News - Yahoo Finance
Aardvark Therapeutics(AARD) Stock Options Chain | Quotes & News - Moomoo
AARD Stock Price, Quote & Chart | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
AARD Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressAnalyst Drop Coverage - The Legal Advocate
AARD stock crashes 34% – here’s why this analyst finds it ‘hard to lean into’ Aardvark at this stage - MSN
Aardvark Therapeutics faces investigation after FDA halts its Phase 3 trial, causing stock to plunge. - Pluang
Aardvark Therapeutics shares plunge 56% after halting Phase 3 trial due to safety concerns. - Pluang
We're Keeping An Eye On Aardvark Therapeutics' (NASDAQ:AARD) Cash Burn Rate - Moomoo
FDA halts Aardvark Therapeutics rare disease study - MSN
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - Barchart.com
FDA halts Aardvark Therapeutics' ARD-101 trial over heart safety concerns, stock now valued mainly for cash. - Pluang
Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path Forward (NASDAQ:AARD) - Seeking Alpha
AARD stock plummets after hours as cardiac safety concerns trigger FDA hold on late-stage program - MSN
FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4 - TipRanks
Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Sahm
Aardvark Therapeutics downgraded to Underperform from Buy at BofA - TipRanks
Under FDA Clinical Hold, Aardvark Therapeutics Seeks Path Forward for Metabolic Drug - MedCity News
Aardvark Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.3, Implies 187% Upside - TradingView
B. Riley Adjusts Aardvark Therapeutics Price Target to $7 From $8, Maintains Buy Rating - Moomoo
Aardvark plummets on FDA clinical hold on Prader-Willi Syndrome asset - Seeking Alpha
Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application - Moomoo
AARD Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Aardvark Therapeutics Could Regain Investor Interest With Upcoming Results -- Market Talk - Moomoo
AARD Stock Crashes 34% – Here’s Why This Analyst Finds It ‘Hard To Lean Into’ Aardvark At This Stage - Stocktwits
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
FDA puts clinical hold on Aardvark’s IND - The Pharma Letter
Aardvark Therapeutics, Inc.Common Stock (Nasdaq:AARD) Stock Quote - The Chronicle-Journal
FDA Halts Aardvark Therapeutics Rare Disease Study - Benzinga
AARD Downgraded by Morgan Stanley -- Price Target Lowered to $3. - GuruFocus
FDA Places Full Hold On Aardvark’s ARD-101 Months After Voluntary Safety Pause - Citeline News & Insights
B. Riley Securities Maintains Aardvark Therapeutics(AARD.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
BTIG downgrades Aardvark Therapeutics stock rating on FDA hold By Investing.com - Investing.com Australia
Aardvark Therapeutics stock tumbles on FDA clinical hold, analyst downgrades - Investing.com Australia
Aardvark Therapeutics Inc Stock (AARD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aardvark Therapeutics Inc Stock (AARD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Dec 11 '25 |
Buy |
14.48 |
7,000 |
101,395 |
1,551,613 |
| Lee Tien-Li | Chief Executive Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,229 |
5,211 |
1,544,613 |
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):